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ABSTRACT: GHMP kinases are a group of structurally
related small molecule kinases. They have been found in all
kingdoms of life and are mostly responsible for catalyzing the
ATP-dependent phosphorylation of intermediary metabolites.
Although the GHMP kinases are of clinical, pharmaceutical,
and biotechnological importance, the mechanism of GHMP
kinases is controversial. A catalytic base mechanism was
suggested for mevalonate kinase that has a structural feature of
the γ-phosphate of ATP close to an aspartate residue; however,
for one GHMP family member, homoserine kinase, where the
residue acting as general base is absent, a direct phosphor-
ylation mechanism was suggested. Furthermore, it was
proposed by some authors that all the GHMP kinases function by a similar mechanism. This controversy in mechanism has
limited our ability to exploit these enzymes as drug targets and in biotechnology. Here the phosphorylation reaction mechanism
of the human galactokinase, a member of the GHMP kinase family, was investigated using molecular dynamics simulations and
density functional theory-based quantum mechanics/molecular mechanics calculations (B3LYP-D/AMBER99). The reaction
coordinates were localized by potential energy scan using an adiabatic mapping method. Our results indicate that a highly
conserved Glu174 captures Arg105 in the proximity of the α-phosphate of ATP, forming a H-bond network; therefore, the
mobility of ATP in the large oxyanion hole is restricted. Arg228 functions to stabilize the negative charge developed at the β,γ-
bridging oxygen of the ATP during bond cleavage. The reaction occurs via a direct phosphorylation mechanism, and the Asp186
in the proximity of ATP does not directly participate in the reaction pathway. Because Arg228 is not conserved among GHMP
kinases, reagents which form interactions with Arg228, and therefore can interrupt its function in phosphorylation, may be
developed into potential selective inhibitors for galactokinase.
GHMP kinases are a group of structurally related small
molecule kinases.1 They have been found in all kingdoms of life
and are mostly responsible for catalyzing the ATP-dependent
phosphorylation of intermediary metabolites. The family is
named after four members (galactokinase (GALK), homoserine
kinase (HSK), mevalonate kinase (MK), and (prokaryotic)
phosphomevalonate kinase (PMK)) and has been expanded to
include archaeal shikimate kinase, L-threonine kinase, N-
acetylgalactosamine kinase (GALK2), glucuronokinase, arabi-
nose kinase, galacturonic acid kinase, mevalonate diphosphate
decarboxylase (MDD), and 4-(cytidine 5′-diphospho)-2-C-
methyl-D-erythritol kinase (CDP-Me kinase).
All of these proteins share a common fold consisting of a
mixture of α-helices and β-sheets, organized into N- and C-
terminal domains which are arranged in a V-shape. This creates
a central cleft, and the active site is located at the base of this
cleft (Figure 1). A number of conserved motifs are
distinguished,2 among which the MgATP binding motifs
(usually denoted II and III) are highly conserved and motif I,
which is involved in recognition of the other substrate, shows
greater variation (Figure 2). Of all the GHMP kinases, GALK is
the best characterized at the structural level, with high-
resolution crystal structures available for a number of
species.3−5
The GHMP kinases are of clinical, pharmaceutical, and
biotechnological importance. Mutations in the gene encoding
MK are associated with hyperimmunoglobulinemia D syn-
drome (HIDS) and mevalonic aciduria (MVA).6−8 Mutations
in the gene encoding human GALK cause the hereditary
disease type II galactosemia.9−12 This enzyme is also an
Received: February 22, 2013
Revised: June 18, 2013
Published: June 20, 2013
Article
pubs.acs.org/biochemistry
© 2013 American Chemical Society 4858 dx.doi.org/10.1021/bi400228e | Biochemistry 2013, 52, 4858−4868
important drug target. Although type II galactosemia is a
relatively mild disease (the main symptom is cataracts, which
can be permanently resolved by surgery), types I and III
galactosemia (caused by mutations in the genes encoding other
galactose-metabolizing enzymes) can lead to severe and
irreversible damage to the liver and brain. The symptoms are
suggested to be caused by accumulation of galactose 1-
phosphate, the product of the phosphorylation catalyzed by
GALK. Therefore, inhibition of the upstream enzyme GALK
would prevent the buildup of toxic galactose 1-phosphate in
types I and III and, in eﬀect, convert them into the far milder
type II. Recently, a number of novel inhibitors of human GALK
have been identiﬁed.13−15 Some other GHMP kinases are also
important drug targets; for example, PMK and CDP-Me kinase
are unique to bacteria and exhibit essential functions in these
organisms and, therefore, are potential targets for novel
antibiotics.16 There has been also increasing interest in the
biotechnological exploitation of some GHMP kinases. GALKs
from several species are being used as biocatalysts, and some
have been engineered to expand their substrate speciﬁcity with
the aim of using the enzyme in the “green chemistry” synthesis
of sugar 1-phosphates, the precursors of carbohydrate-
containing antibiotics.17−19
The mechanism of GHMP kinases is controversial. The
structure of MK shows that mevalonate and the γ-phosphate of
ATP are close to an aspartate residue, which is largely
conserved among GHMP kinases.20 It was postulated that
this residue acts as a general base, abstracting a proton from the
hydroxyl group in mevalonate. This converts mevalonate into
an excellent nucleophile, which then attacks the γ-phosphorus
of ATP. A nearby lysine residue was believed to maintain the
aspartate residue in the deprotonated state and lower the pKa of
the sugar to facilitate the proton transfer. This catalytic base
mechanism was supported by site-directed mutagenesis
studies.20 Removal of the putative active site base reduces the
rate substantially. Similarly, the rate is reduced by alteration of
the lysine residue.21,22 Similar arrangements of the active site
residues are observed in most of the other GHMP kinases, such
as GALK, where arginine (Arg37) replaces lysine. Recently a
combined molecular modeling and mutagenesis study revealed
that removal of the putative active site base (Asp186) in human
GALK results in destabilization of the protein and loss of
detectable activity, as does removal of the adjacent cationic
residue Arg37.23 Preliminary quantum mechanics/molecular
mechanics (QM/MM) calculations suggested that Asp186
appeared to polarize the hydroxyl group in the sugar. However,
whether this results in bond breakage or weakening is unclear,
and the role of the surrounding residues in the active site is not
understood.23
In HSK, another member of the GHMP family, the aspartate
and lysine in the proximity of ATP are replaced with asparagine
and threonine, respectively; therefore, HSK does not have a
corresponding base to activate the hydroxyl group in the
substrate. Instead, the γ-phosphoryl group directly grabs a
proton from the hydroxyl group of homoserine (Hse). This
direct phosphorylation mechanism represents another possible
mechanism for GHMP kinases.24 Structural studies on N-
acetylgalactosamine kinase (GALK2) suggested that this
mechanism may occur even in those enzymes which have a
basic residue in the active site. The authors of this study
considered that the relevant aspartate (Asp190) was too far
from the sugar to abstract a proton.25 This was supported by
the lack of a pH eﬀect on the steady-state kinetic parameters of
some of the enzymes, e.g., S. cerevisiae GALK (Gal1p),26a and
the lack of a deuterium kinetic isotope eﬀect in the human
enzyme.26b However, either of the two proposed mechanisms
for GHMP kinases might work for human GALK1.2,25
Previous studies of GALK inhibitor discovery have been
focused on high-throughput screening.13−15 Development of
“suicide” inhibitors has become an interesting area because this
represents a potentially eﬀective strategy for selective inhibition
of the kinase. Recently, mechanism-based inhibitors were
designed to inactivate mevalonate pathway GHMP kinases.27
However, the controversy about the mechanism in GHMP
kinases has limited our ability to exploit these enzymes as drug
targets and in biotechnology.
The mechanism of GHMP kinases can be elucidated by
investigation of the reaction pathway by theoretical calculation,
which is not approachable by experiments. In the present work,
the phosphorylation reaction mechanism of GALK was studied
by molecular dynamics simulation and hybrid QM/MM
calculations. It was demonstrated that the reaction’s phosphor-
ylation mechanism occurs via direct phosphorylation, instead of
the previously hypothesized catalytic base mechanism. The
dynamic aspect of the GALK structure, in particular the
structure in complex with the transition state, would provide a
starting point for rational design of mechanism-based GALK
inhibitors and provide guidance for biotechnology research into
broadening the speciﬁcity of the enzyme.
■ MATERIALS AND METHODS
Protein Preparation. Chain A of the crystal structure of
human GALK (PDB code 1WUU) was used.3 Ser230 and
Leu231, which are missing in the experimentally resolved
structure, were built using the loop reﬁnement tools in
Discovery Studio 2.5 (Accelrys, Inc.). The selenomethionine
residues were mutated back to standard methionine, and the
nitrogen atom bridging the β- and γ-phosphates in the bound
AMP.PNP was altered to an oxygen atom yielding an ATP
molecule. Two water molecules were added to saturate the
coordination of Mg2+ based on the positions of the two
coordinated waters in the crystal structure of GALK2.25 The
Figure 1. Crystal structure of human GALK. The N-terminal domain
is cyan, and the C-terminal domain is green. Motifs I−III are purple.
The galactose and ATP in the active siet are shown by a stick model,
and the Mg2+ ion is shown as a purple ball.
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protonation states of histidines in GALK were examined using
protein preparation in Maestro (Schrödinger, Inc.).
Molecular Dynamics Simulation. Molecular dynamics
(MD) simulation was performed using the AMBER 10 package
(University of California).28 The Amber Parm 99 force ﬁeld
parameters were used.29 The partial charges of galactose, Mg2+,
and ATP were obtained by single-point charge calculation at
the HF/6-31G(d) level of theory using the Gaussian 09
Figure 2. Sequence alignments of the GHMP kinases with their homologue kinase PoKs using the MUSCLE multiple-sequence alignment server
from the European Bioinformatics Institute. Sequence alignments of 11 representative GHMP and 3 PoK kinases are shown. The three ATP binding
motifs I−III are labeled with red boxes. The positions of residues Arg37, Arg105, Glu174, Asp186, and Arg228 are highlighted by green arrows.
Protein name abbreviations are as follows: GALK, galactokinase; MK, mevalonate kinase; PMK, phosphomevalonate kinase; HSK, homoserine
kinase; MDD, mevalonate diphosphate decarboxylase; PoK, pantoate kinase; PanK, pantothenate kinase; AK, archaeal kinase; HP, hypothetical
protein; UNK, unknown. Species name abbreviations are as follows: Hsa, Homo sapiens; Sce, Saccharomyces cerevisiae; Pfu, Pyrococcus furiosus; Spn,
Streptococcus pneumoniae; Mja, Methanococcus jannaschii; Tko, Thermococcus kodakarensis; Tba, Thermococcus barophilus; Hwa, Haloquadratum
walsbyi; Hba, Halobacterium sp. NRC-1. Accession numbers: Hsa-GALK1 (P51570.1), Hsa-GALK2 (Q01415.1), Sce-Gal1p (NP_009576.1), Sce-
Gal3p (NP_010292.1), Pfu-GALK (AAL80569.1), Mja-MK (AAB99088.1), Hsa-MK (NP_000422.1), Spn-PMK (NP_357934.1), Sce-PMK
(AAA34596.1), Mja-HSK (AAB99107.1), Hce-HSK (P17423.4), Tko-PoK (Q5JHF1.1), Tba-PoK (YP_004072154.1), Hwa-PoK (CAJ51400.1).
Other GHMP kinase or PoK homologous sequences used for the alignment but not shown are Has-MDD (NP_002452.1), Hba-HP (AAG18848.1),
Archaeoglobus fulgidus HP (AAB89596.1), Mja-HP (AAB98974.1), Methanopyrus kandleri AK (AAM01947.1), Pyrobaculum aerophilum HP
(AAL64892.1), Aeropyrum pernix HP (BAA80948.2), Sulfolobus solfataricus HP (AAK42544.1), Cenarchaeum symbiosum AK (ABK78124.1),
Haloarcula marismortui UNK (AAV46584.1), Methanococcoides burtonii MDD (ABE52109.1), Methanococcus maripaludis HP (CAF29954.1),
Methanosaeta thermophila PanK (ABK15208.1), Methanosarcina acetivorans HP (AAM04698.1), Methanosarcina barkeri PanK (AAZ72136.1),
Methanosarcina mazei (AAM31978.1), Methanosphaera stadtmanae AK (ABC57568.1), Methanospirillum hungatei PanK (ABD40583.1),
Methanothermobacter thermautotrophicus (AAB85083.1) Natronomonas pharaonis PoK (CAI48513.1), Nitrosopumilus maritimus GHMP kinase
(ABX13614.1), Pyrococcus abyssi AK (CAB49305.1), P. furiosus HP (AAL81993.1), Pyrococcus horikoshii HP (BAA30946.1), Sulfolobus acidocaldarius
AK (AAY80312.1), and Sulfolobus tokodaii HP STK_05300 (BAB65525.1).
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package,30 and the RESP partial atomic charges were obtained
using antechamber encoded in AMBER 10. The protein was
soaked with a TIP3P water box with a minimum distance of 8 Å
to the boundary of the protein. The size of the box was 70.504
× 82.631 × 87.672 Å3. Seven sodium ions were added into the
water box to maintain the neutral system.
The protein together with the ligand (ATP) and the
substrate (galactose) was subjected to 1250 steps of steepest
descent minimization followed by 1250 steps of conjugate
gradient minimization with a restrained force constant of 0.5
kcal mol−1 A−2.31 The system was then heated moderately from
0 to 300 K for 50 ps, using the Langevin dynamics method32
with a collision frequency of 5.0 ps−1. A periodic boundary
condition was applied, and equilibration was carried out with
the NVT ensemble at 300 K for another 50 ps without
harmonic constraints. The particle mesh Ewald method33 was
used to consider the long-range electrostatic interactions. The
cutoﬀ distance of nonbonded van der Waals force was 10 Å.
The SHAKE method34 was used to constrain the covalent
bonds involving hydrogen atoms. A time step of 1 fs was used,
and 5 ns MD simulation was performed with the NPT
ensemble at a reference pressure of 1 atm at 300 K. Cluster
analysis of the MD trajectory was performed by ptraj command
encoded in the AMBER 10 package.
QM/MM Simulation. The QM/MM calculations were
performed by a two-layer ONIOM method (B3LYP-D,
AMBER)35,36 implemented in Gaussian 09 (Gaussian, Inc.).
The truncated Asp186, Arg37, Ser142, Glu174, Arg228, and
ATP as well as galactose, Mg2+ ion, and two structural waters
(49 heavy atoms in total) were treated as a high-level layer by a
DFT-QM method, and the rest of the system was treated as a
lower-level layer by a MM method (Figure 3).
The overall charge of the QM region is −2. The QM region
was optimized at the B3LYP-D/6-31G(d) level of density
functional theory,37 and the MM region was optimized by the
Amber Parm 99 force ﬁeld. The electronic embedding scheme
was used in the QM/MM study. It incorporates the partial
charges of the MM region into the quantum mechanical
Hamiltonian and allows the QM wave function to be polarized.
To accelerate the calculation, a reduced system including the
residues within 12 Å of the active site was used in a potential
energy surface scan, using a protocol developed by Tao and co-
workers.38,39 Residues within 6 Å of the active site (included)
were allowed to move while the others were frozen (Supporting
Information, Figure S1).
The pKa of the protein was calculated based on the QM/
MM-minimized structure using PROPKA 2.0.40,41
Simulations of Mutated Human GALK. Five mutated
proteins of human GALK were modeled, namely, E174D,
E174Q, R105M, R228K, and R228M. The mutated protein
structures were subjected to 2500 steps of steepest descent
followed by 2500 steps of conjugate gradient minimization; 5
ns MD simulations were then performed for each minimized
mutated proteins, using the same parameters as those used for
the wild-type human GALK. The representative conformations
for each mutant were retrieved from MD simulations by cluster
analysis.
■ RESULTS AND DISCUSSION
In the crystal structure of human GALK, the Mg2+ ion is
coordinated to Ser142 and to the α-, β-, and γ-phosphate
oxygen atoms. The coordinates of the covalent waters were not
resolved. By comparison with the crystal structures of the
reactant and product of GALK2,25 the positions of two
coordinated water molecules in GALK were modeled. This
structure was used as the starting structure for investigation of
the reaction mechanism of GALK.
The uncertainty in determination of the position of atoms
using an X-ray crystallography method can be addressed by MD
methods.42 MD simulations were performed to obtain a
dynamic structural model of human GALK in aqueous solution.
The parameters for ATP, galactose, and magnesium ion
obtained by ab initio calculation are shown in the Supporting
Information, Table S1.
The conformations obtained from the MD trajectory were
clustered into distinct sets on the basis of the RMSD values of
the backbone carbon atoms. According to the RMSD values of
the backbone carbon atoms, galactose, and ATP (Supporting
Information, Figure S2), the last 3.2 ns of the MD simulation
was shown to reach equilibrium and was used for cluster
analysis. In total, 10 representative conformations were
retrieved from the MD trajectory (Supporting Information,
Table S2).
The phosphate binding loop (P-loop) is a motif in proteins
which were initially reported by Walker and co-workers in
1983.43 It was suggested that the lysine at the end of the P-loop
is of great importance for nucleotide binding, stabilizing the
negative charge that develops at the β,γ-bridging oxygen of
ATP during bond cleavage.44 GHMP superfamily members
share a consensus sequence (PXXXGLXSSAA) that has been
shown to form a unique P-loop structure.45−47 The unique loop
located on the N-terminus of an α-helix near the conserved
ATP binding motif II forms a larger than normal oxyanion hole.
Among the features that distinguish the nucleotide binding
pocket of GHMP kinases from the P-loop of common kinases
is the fact that the catalytic lysine residue is “missing” in the
GHMP P-loop. The glycine-rich P-loop in human GALK
(P134LGGLSSSAS144) allows for ﬂexible movement of the loop.
The Mg2+ ion is coordinated to the α-, β-, and γ-phosphate
oxygen atoms of the ATP in GALK. Similar Mg2+ coordination
environments are observed in other ATP-binding kinases such
Figure 3. QM/MM partition of the protein. The inner QM core
including galactose, ATP, Mg2+, two structural water molecules, Arg37,
Asp186, Glu174, and Arg228 is treated by B3LYP-D method, and the
outer layer is treated by molecular mechanics using AMBER force
ﬁeld.
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as CheA histidine kinase, epidermal growth factor receptor
(EGFR) ErbB3 kinase, and cyclin-dependent protein kinase
(CDK2). The reaction mechanism of ErbB3 kinase is direct
phosphorylation via a transition state in which the proton on
the substrate hydroxyl group is transferred to the γ-phosphate
of ATP, whereas reaction in CDK2 occurs through a catalytic
base mechanism where the phosphate transfer is preceded by
proton transfer from the hydroxyl group of the substrate to a
surrounding aspartic acid.48−50 A lysine residue in the active
sites of these kinases was shown to stabilize the nucleophilic
β,γ-bridging oxygen atom of the ATP during bond cleavage,
either directly or via a H-bond network with water molecules.
However, no cationic residue is observed at the active site in
the crystal structure of human GALK. The closest cationic
residue, Arg228, which is located on a surface loop adjacent to
the P-loop, is 7.29 Å from the β,γ-bridging oxygen. We
postulated that Arg228 in the inactive conﬁguration may play a
role in the enzymatic reaction. The MD simulation trajectory
was inspected, and the distance between the distal guanidinium
nitrogen atom of Arg228 and the β,γ-bridging oxygen atom of
the ATP was plotted (Supporting Information, Figure S3).
Interestingly, it was found that with time evolution Arg228
approaches the β,γ-bridging oxygen, with the distance rNη−Oβ3
decreasing from 7.3 to 3.6 Å (Supporting Information,
supplementary movie). Thus, the structure has turned into an
active conﬁguration in which Arg228 is prone to stabilizing the
negative charge developed at the β,γ-bridging oxygen during
bond cleavage.
The representative conformations retrieved from cluster
analysis of the MD simulation trajectory were carefully
inspected to compare the conformational diﬀerence around
the ATP binding site, in particular the distance between the C1
hydroxyl oxygen atom of galactose and the Pγ atom of ATP
(rO1− Pγ) and the distance between the C1 hydroxyl hydrogen
atom of the sugar and the carboxylate OD2 atom of Asp186
(rH1− OD2) because these distances indicate preference of either
catalytic base or direct phosphorylation reaction mechanisms.
The conformation where Arg228 was closest to ATP
(Supporting Information, Figure S3 and Table S2) was selected
from the 10 representative structures for the subsequent QM/
MM mechanistic study, as Arg228 in this conformation has the
potential to stabilize the β,γ-bridging oxygen of ATP during
phosphorylation. The pKa of Arg228 in the QM/MM-
optimized reactant of human GALK was calculated, and it
was found that the value (9.47) is much lower than the “free
solution” value of arginine (12.50). This indicates that Arg228
may act as a potential electrophile to stabilize the negative
Figure 4. (A) Reaction path of human GALK determined by adiabatic mapping. The x and y axes are the distance between the γ-phosphate P atom
and the C1 hydroxyl oxygen atom of galactose, rPγ−O1, and that between the γ-phosphate P atom and the β,γ-bridging oxygen of the ATP, rOβ3−Pγ,
respcetively. The z axis is the energy with units of kilocalories per mole. (B) Structures of the reactant, TS, and the product obtained by QM/MM
calculations with B3LYP-D/6-31G(d) level of theory for the QM part and the AMBER force ﬁeld for the MM part. The distance between the
nitrogen atom of Arg228 and the β,γ-bridging oxygen is labeled by dotted green lines, and rOβ3−Pγ and rPγ−O1 are labeled by black dotted lines.
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charge developed at the β,γ-bridging oxygen of ATP during
bond cleavage.
Recently, a glutamate residue (Glu134) was suggested to be
involved in the catalytic reaction of pantoate kinase (PoK), a
GHMP kinase necessary for coenzyme A biosynthesis in the
Archaea.51 The glutamate is largely conserved among GHMP
kinases, and the corresponding residue in human GALK
(Glu174) is located on an α-helix (Figure 2). From the
molecular dynamics simulation, it was observed that Arg105
ﬂipped toward Glu174 and ATP and ultimately formed a strong
electrostatic interaction with Glu174 (Figure S4).
Combined QM/MM methods are important in the under-
standing of the mechanism of enzyme-catalyzed reactions.52
The conformation selected from the cluster analysis was
optimized using QM/MM methods. It was found that in the
optimized geometry, Arg105 becomes closer to ATP because of
a favorable ionic interaction with Glu174; in the meantime, it
forms an H-bond with the α-phosphate atom of ATP, thus
restricting the movement of ATP in the large oxyanion hole
(Figure 4). The potential energy surface (PES) of the human
GALK reaction pathway was investigated by the adiabatic
mapping method. On the basis of the optimized reactant, the
distances of rO1−Pγ and rPγ−Oβ3 that are directly involved in γ-
phosphate transfer were scanned with an increment of 0.1 Å.
A trigonal-bipyramidal transition state that connects the
reactant and the product was identiﬁed from the PES (Figure
4). It was validated by a unique imaginary frequency of −167.59
cm−1 that corresponds to the γ-phosphate transfer to the
substrate galactose. The reaction coordinates exhibited proton
migration from the C1 hydroxyl group of galactose to the γ-
phosphate oxygen atom of ATP, and the phosphoryl transfer
coincides with the proton migration from galactose (Scheme
1). Compared with that of the reactant, the distance between
the C1 hydroxyl oxygen and the Pγ atom in the transition state
is shortened from 3.44 to 2.06 Å and the distance between Pγ
and the Oβ3 atom increased from 1.75 to 2.00 Å (Figure 4).
The associative or dissociative character of the transition state
was estimated using Pauling’s formula: D(n) = D(1) − 0.6 log
n.53 Here, D(1) is 1.73 Å for the P−O bond and D(n) is the
average of rO1−Pγ and rPγ−Oβ3 at the transition state (2.03 Å). The
fractional bond number (n) is 0.32, which gives a dissociative
character of 68%. Thus, the phosphoryl transfer in GALK
occurs through a dissociative-dominated mechanism. The
calculated activation barrier is 20.8 kcal/mol, in accordance
with a previous kinetics study (kcat = 4.7 ± 0.2 s
−1) that showed
that the phosphorylation reaction catalyzed by human GALK
occurs very readily.54
Arg228, Glu174, and Arg105 in human GALK were mutated
in order to understand the eﬀect of the mutations on the
Scheme 1. Two-Dimensional Representation of the Phosphorylation Mechanism of Human GALK
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conformation of the active site. When Arg228 is mutated into
neutral methionine, Arg105 failed to access the active site
(Figure 5). One structural water molecule moved away, yielding
an unstable pentacoordinated Mg2+ ion. Interestingly, when
Arg228 was replaced by a conservative lysine, Arg105 remained
far from Glu174. This suggests Arg228 helps to grasp Arg105 in
the proximity of the active site in wild-type human GALK.
Little eﬀect was observed for conservative replacement of
Glu174 with an aspartate, although Arg105 is not as close to the
catalytic center as is the wild-type GALK. Arg228 is positioned
preferably toward the β,γ-bridging oxygen atom of ATP, and
the hydrogen atom on the C1 hydroxyl group of galactose is
well-positioned toward the oxygen atom of γ-phosphate.
However, when Glu174 was replaced by a neutral glutamine,
the octahedral coordination of the Mg2+ ion is distorted
because of drifting of the Mg2+ ion and a catalytic water
molecule.
Replacement of Arg105 by a neutral methionine caused
drifting of all the ligands. Glu174 moved toward the reaction
center such that it was eventually covalently bonded to the
Mg2+ ion, replacing one catalytic water molecule in the wild-
type GALK. Proximity of the negatively charged Glu174 makes
the trigonal-bipyramidal transition state highly unstable. Thus,
in addition to Arg228, it may be essential to have Arg105 as the
second positively charged residue in the ATP binding site to
further stabilize the charge in the unusual oxyanion hole of
GALK.
Thus we propose it is important to have a positively charged
arginine Arg228 around the β,γ-bridging oxygen atom of ATP
to stabilize the coordination environment of the Mg2+ ion. It
helps to bring a second positively charged residue (Arg105) to
the proximity of ATP. Glu174 and Arg105 are also important in
stabilizing the octahedral coordination, although they are not
indispensable for retaining Arg228 around ATP.
Lys101 located on the P-loop in the active site of PMK was
suggested to stabilize both the reactant and the transition state
of the kinase.55 The residue is not conserved in GHMP kinases
(Figure 2). However, a cationic residue located in the proximity
of the β,γ-bridging oxygen is observed in many GHMP kinase
structures, for example, Lys234 in human GALK2,25 Lys192 in
P. furiosus GALK,5 Lys266 in S. cerevisiae Gal1p4, and Lys258 in
S. cerevisiae Gal3p.56 These lysine residues are all located at a
loop adjacent to their respective P-loops (Figure 6 and
Supporting Information, Figure S5). Comparison of the
reactants and products of human GALK and GALK2 showed
that the distal guanidinium nitrogen atom of Arg228 is 4.07 Å
from the β,γ-bridging oxygen in human GALK, whereas the ε-
amino nitrogen atom of Lys234 is closer to the β,γ-bridging
oxygen in GALK2 (with the rOβ3−NK234 of 2.96 Å) and the γ-
phosphate is better positioned for the nucleophilic attack by the
sugar substrate GalNAc (with rPγ−O1 of 3.10 Å) (Supporting
Information, Figure S6). In the phosphorylation products of
both kinases, the arginine or lysine further approaches the β,γ-
bridging oxygen and the distances rOβ3−NK234 and rOβ3−NR228
Figure 5. Mutated human GALK structures from MD simulations. The Mg ion is shown in maroon, and the oxygen atoms in the structural water
molecules are shown by red balls. The Cα atoms of the mutated residues are shown in orange by CPK mode. (A) The wild-type human GALK, (B)
E174D, (C) E174Q, (D) R105M, (E) R228K, and (F) R228M.
Biochemistry Article
dx.doi.org/10.1021/bi400228e | Biochemistry 2013, 52, 4858−48684864
become similar to each other. Thus, Arg228 in human GALK
may play a role similar to that of the lysine in other GALK and
PMK kinases by stabilizing the negative charge developed on
the β,γ-bridging oxygen atom during bond cleavage. It is worth
noting that Arg228 is far from the β,γ-bridging oxygen
(rOβ3−NR228 is 7.30 Å) in the crystal structure of human GALK,
which represents an inactive conﬁguration. However, with time
evolution, it gradually approaches the active site because of the
ﬂexibility of the loop on which it is located and therefore exerts
its function in phosphorylation.
Arg241 in the mammalian MK is invariantly present in MK
kinases and was proposed to stabilize the substrate by forming
an ionic bond with the carboxylic group of mevalonate.20
Similar to Arg228 in GALK, Arg241 in the crystal structure of
the mammalian MK is located on the surface loop adjacent to
the P-loop (Figure 6), although it is also far from the β,γ-
bridging oxygen (7.77 Å) (Supporting Information, Figure
S7).20 Thus, we speculate the crystal structure of MK is also in
its inactive conﬁguration and the arginine in the vicinity of the
P-loop may approach the triphosphate tail of ATP through
substantial conformational change to stabilize the negative
charge that develops at the β,γ-bridging oxygen of ATP during
bond cleavage.
Arg234, an invariant arginine in HSK kinases, was found to
be essential for the catalytic eﬃciency of Escherichia coli HSK by
forming a strong salt bridge with the carboxylate of Hse.24
Surprisingly, the conserved Arg235 in Methanocaldococcus
jannaschii HSK is located on a helix far from the ATP binding
pocket (Figure 6). The absence of a cationic residue in the
triphosphate binding pocket makes HSK distinct from other
GHMP kinases. Arg235 may participate in stabilizing the β,γ-
bridging oxygen of ATP facilitated by the surrounding water
molecules. Further investigation is required to elucidate the
reaction pathway in HSK and understand the diﬀerence in
mechanism among GHMP kinases.
Recently, several small lead compounds were reported to
selectively inhibit GALK with high potency.14 Among them,
compound 24 forms H-bond interactions with Arg228, Glu174,
and Arg105. Because Arg228 is not conserved among GHMP
kinases, reagents which form interactions with Arg228, and
Figure 6. Location of the lysine or arginine residues near the P-loops of GHMP kinases. The ﬁgure was generated by superimposing the conserved
motifs I and II of the GHMP kinases. P-loops are shown in green. The loop on which Arg228 is located in GALK is shown in plum, and helix Arg235
in HSK is shown in orange. (A) QM/MM-optimized reactant of human GALK, (B) reactant of human GALK2 (PDB code 2A2D), (C) gal3p (PDB
code 3V2U), (D) Spn-PMV (PDB code 3GON), (E) rat MK (PDB code 1KVK), and (F) Mja-HSK (PDB code 1H74). The pose of Hse was
modeled based on the structure of HSK bound with ANP (PDB code 1H72).
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therefore can interrupt its function in the phosphorylation, may
be developed into potential selective inhibitors for GALK. On
the other hand, substrate speciﬁcity of the kinase may be
broadened by altering Arg228 as well as the loop where it is
located in relation to the corresponding loops in other GHMP
kinases.
■ CONCLUSION
The GHMP kinase superfamily plays a signiﬁcant role in
various biological pathways. Previously, there was no detailed
mechanistic study at the atomic level for the GHMP kinase
superfamily. Here, GALK involved in the ﬁrst committed step
in the Leloir pathway was studied in detail by combined
molecular dynamics and hybrid QM/MM methods. We
demonstrated that Glu174 captured Arg105 in the proximity
of ATP via an H-bond network, thus restricting the movement
of ATP in the large anion hole. Because of the loop ﬂexibility,
Arg228 approaches the ATP and stabilizes the negative charge
developed at the β,γ-bridging oxygen atom of the ATP during
bond cleavage. The optimized structure of the transition state
and the reaction pathway obtained by QM/MM study disclosed




The parameters for galactose, magnesium ion, and ATP; a
movie of MD simulation; and the coordinates of the stationary
points on the PES surface. This material is available free of
charge via the Internet at http://pubs.acs.org.
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